- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04712786
Refractive Changes Following Vitrectomy
Refractive Changes in Pseudophakic Eyes Following Vitrectomy With or Without Gas Tamponade
Study Overview
Status
Intervention / Treatment
Detailed Description
This research was reviewed by an independent ethical review board and conforms with the principles and applicable guidelines for the protection of human subjects in biomedical research. This was a retrospective, comparative case series including pseudophakic patients who underwent PPV. Group 1 consisted of patients with pseudophakic RRD who underwent PPV and 12% perflouropropane (C3F8) gas tamponade whereas Group 2 consisted of patients with ERM or VH who underwent PPV without any tamponade between February 2015 and March 2019 at Bursa Retina Eye Hospital. Informed consent was obtained from all the participants. The study was in line with the ethical standarts of the Helsinki Declaration
Patient eligibility Patients who underwent uncomplicated cataract surgery with phacoemulsification and in-the-bag IOL implantation and subsequent neodymium:yttrium-aluminum-garnet (Nd:YAG) laser due to capsular opacification were included. Preoperative refractive data obtained after Nd:YAG laser and six months prior to vitrectomy surgery. Postoperative refractive data was obtained at 12 months after vitrectomy. Eyes with a preoperative spherical refractive error > ±6 D or cylindrical refractive error > ±3 D were excluded. Also eyes with corneal disorders were excluded.
Ocular parameters
All patients underwent complete ophtalmic examination including best corrected visual acuity (BCVA) in the logMAR scale, slit-lamp examination, intraocular pressure (IOP) assessment, fundus examination and autokeratorefractometry (auto kerato-refractometer KR-8800 from Topcon, Tokyo, Japan) at preoperative and postoperative month-12. Induced astigmatism values were calculated through vector analysis.
Surgical procedures
All surgeries were performed by the same surgeon (S.Y.). Retrobulbar block anesthesia (a mixture of 2 ml of lidocaine hydrochloride 2% and 2 ml of bupivacaine hydrochloride 0.5%) was used. Three port 23-gauge (G) transconjunctival PPV was performed using the vitrectomy system DORC (Dutch Ophthalmic Research Center, Zuidland, Netherlands) and Zeiss microscope with EIBOS 2 (Haag Streit, Mason, OH, USA) attachment for non-contact fundus viewing.
In group 1, all patients underwent a near-complete vitrectomy including base shaving, laser endo-photocoagulation and C3F8 gas tamponade. In group 2, patients with ERM received a limited vitrectomy including; core vitrectomy, induction of a posterior vitreous detachment if not present and peeling of the ERM and inner limiting membrane (ILM). Peripheral retina was examined with indentation to identify any retinal breaks. Neither laser endo-photocoagulation, nor gas tamponade and vitreous base shaving was performed. For patients with VH patients, a near-complete vitrectomy, including base shaving, laser endo-photocoagulation was performed except for gas tamponade. In both groups, the sclera is sutured with 8-0 polyglactin suture (Vicryl) in case of wound leakage.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Bursa, Turkey, 16130
- Retina Eye Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria
- Patients aged ≥ 18 years
- Pseudophakic patients who underwent pars plana vitrectomy
Exclusion Criteria
- Patients aged 18 years >
- Patients with a spherical refractive error > ±6 D
- Patients with a cylindrical refractive error > ±3 D
Study Plan
How is the study designed?
Design Details
- Observational Models: Other
- Time Perspectives: Retrospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Group
27 patients, Group 1 consisted of patients with pseudophakic rhegmatogoneous retinal detachment who underwent pars plana vitrectomy and 12% perflouropropane (C3F8) gas tamponade and 20 patients Group 2 consisted of patients with epiretinal membrane or vitreous hemorrhage who underwent PPV without any tamponade
|
23 gauge pars plana vitrectomy was performed for retinal detachment, vitreous hemorrhage or epiretinal membrane
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The rate of spherical and cylindrical refractive changes
Time Frame: 12 months
|
Changes in spherical and cylindrical refractive error 12 months after pars plana vitrectomy
|
12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Sami Yılmaz, MD, Bursa Retina Eye Hospital
- Study Director: Remzi Avcı, Professor, Bursa Retina Eye Hospital
- Principal Investigator: Aysegul Mavi Yıldız, MD, Bursa Retina Eye Hospital
Publications and helpful links
General Publications
- Hamoudi H, Kofod M, La Cour M. Refractive change after vitrectomy for epiretinal membrane in pseudophakic eyes. Acta Ophthalmol. 2013 Aug;91(5):434-6. doi: 10.1111/j.1755-3768.2012.02574.x. Epub 2012 Sep 23.
- Byrne S, Ng J, Hildreth A, Danjoux JP, Steel DH. Refractive change following pseudophakic vitrectomy. BMC Ophthalmol. 2008 Oct 13;8:19. doi: 10.1186/1471-2415-8-19.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BursaRetinaEyeH
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Refractive Errors
-
Suzan A RattanCompletedRefractive Errors | Refractive SurgeryIraq
-
London School of Hygiene and Tropical MedicineBritish Council for Prevention of Blindness; Tanzanian Society for the BlindCompletedUnder- and Uncorrected Significant Refractive ErrorsTanzania
-
Johnson & Johnson Vision Care, Inc.TerminatedRefractive Error CorrectionUnited States
-
Chulalongkorn UniversityNot yet recruitingRefractive Errors
-
Johnson & Johnson Vision Care, Inc.CompletedRefractive ErrorUnited States
-
Alcon ResearchCompleted
-
Alcon ResearchCompletedRefractive ErrorsUnited States
-
Alcon ResearchCompletedRefractive ErrorsUnited States
-
Wang HongxiaTianjin Eye HospitalUnknownRefractive ErrorChina
Clinical Trials on pars plana vitrectomy
-
PharmaBio CorporationRecruitingMyopic Chorioretinal AtrophyJapan
-
Ospedale Policlinico San MartinoRecruitingRetinal Detachment | PArs Plana Vitrectomy | Silicone Oil Droplets on Intraocular LensItaly
-
Ospedale Policlinico San MartinoRecruiting
-
Omer Othman AbdullahTerminated
-
Minia UniversityCompleted
-
AllerganCompletedVitrectomyUnited States
-
Benha UniversityRecruiting
-
Benha UniversityRecruitingRetinal Detachment | Proliferative VitreoretinopathyEgypt
-
Aier School of Ophthalmology, Central South UniversityUnknownRetinal Disease | Macular RetinoschisisChina
-
National Taiwan University HospitalCompleted